The Consumer-Driven Health Care Institute (CDHCI) is a not-for-profit organization representing the leaders in consumer-driven health care. CDHCI's goal is to be the prime source for education, research and information about consumer-driven health care. The Institute actively promotes the shift to the Consumer-Driven Health paradigm.
The Member Companies have created health care models and technologies that empower individuals to make informed health care choices.
CDHCI believes that:
- Consumers will work with their physicians and health care providers to create a better health care outcome for themselves and their families.
- Health care usage is more cost efficient with empowered and knowledgeable consumers who use information tools.
- Price and quality transparency about health care professionals is a key method for effective consumer health care choices.
CDHCI is proud to sponsor and endorse the 2013 Health Care Payments and Policy Conference to be held again in Washington, DC. Together, with our member organizations, we are planning additonal events and forums designed to provide the latest industry information and future trends as well as up to the minute policy information from Washington. Please Click on the logo below to register for all of our sponsored our events and receive updates about HCON 2013.
CDHC Market Data Advisory Service
The Consumer Driven Healthcare (CDHC) Market Data Advisory is a report published quarterly by The Consumer Driven Healthcare Institute (CDHCI). The CDHC Market Data Advisory was developed to help CDHC program administrators, financial institutions, health plans, and other key players in the CDHC market eco-chain better understand both macro and micro-industry trends for use in strategy, business development, and to enable them to achieve greater efficiencies in their own programs. Click here to request information about our data services
CDHCI Sponsor Organizations
| CDHCI News|
|2013 Healthcare Payments & Policy Conference|
The 2013 Healthcare Payments and Policy Conference (HCON2013) will again be held in Washington, DC. As with past events, speaker faculty include over thirty industry leaders, leading academics and health policy makers who will discuss trends and new innovations impacting and driving the healthcare payments industry. The 2013 HCON will feature U.S Rep. Tom Price, M.D. and Kevin Yang, Chief Information Officer, Maryland Health Benefit Exchange. CLICK below to receive updates about HCON 2013 as well as future events sponsored by CDHCI... Click Here for More ...
|Appeals Courts Issue Conflicting Rulings on Health-Law Subsidies|
Two U.S. appeals courts issued conflicting rulings on whether consumers can get subsidies for health coverage bought on the Affordable Care Act's federal exchange, escalating a legal battle that could complicate fall insurance enrollment and jeopardize tax credits for millions of Americans.In a blow to President Barack Obama's signature legislative achievement, a panel of the U.S. Court of Appeals for the District of Columbia Circuit, on a 2-1 vote, invalidated an Internal Revenue Service regulation that implemented a...
Click Here for More ...
Wall Street Journal
|Implementing Health Reform: Appellate Decisions Split On Tax Credits In ACA Federal Exchange |
July 22, 2014 was arguably the most important day in the history of the implementation of the Affordable Care Act since the Supreme Court issued its ruling in the National Federation of Independent Business case in June of 2012. As no doubt most readers of this blog know by now, shortly after 10 a.m. the United States Court of Appeals for the District of Columbia Circuit handed down its decision in Halbig v. Burwell. Two judges ruled over a strong dissent that an Internal Revenue Service rule allowing federally facilitated exchanges to issue premium tax credits to low and moderate income Americans is invalid Click Here for More ...
|What Smart People Never Buy At The Drugstore|
A 100-pill package of CVS-brand aspirin costs $1.14 on the company's website, while pharmaceutical giant Bayer's version sells for $6.99. Yet time and time again, the typical shopper chooses the pricier brand-name drug, even though it's essentially the same, according to a recent study by Dutch economist Bart J. Bronnenberg and three University of Chicago professors....
Click Here for More ...
|Who Gets Saved? Hepatitis Cure at $84,000 Makes Doctors Choose|
Early this year, liver specialist Ken Flora and his colleagues sent letters to 1,300 patients announcing exciting news: powerful new drugs to cure the lethal hepatitis C virus were finally available. Soon after, some patients received a different message: notices that their health plans were refusing to pay for the $84,000 drug. So far only about 50 of the patients have received the medicine, Gilead Sciences Inc.’s Sovaldi.
Click Here for More ...